These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7723497)

  • 21. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies.
    Wang S; Dai Y; Chen L; Dong Z; Chen Y; Li C; Zhong X; Lin W; Zhang J
    PLoS One; 2013; 8(9):e75285. PubMed ID: 24098690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound.
    Pfohl M; Athanasiadis A; Koch M; Clemens P; Benda N; Häring HU; Karsch KR
    J Am Coll Cardiol; 1998 Apr; 31(5):987-91. PubMed ID: 9561998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
    Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
    Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty.
    Hamon M; Amant C; Bauters C; Richard F; Helbecque N; Passard F; McFadden EP; Lablanche JM; Bertrand ME; Amouyel P
    Am J Cardiol; 1998 Jan; 81(1):79-81. PubMed ID: 9462611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and the Risk for Restenosis After PTCA.
    Völzke H; Hertwig S; Rettig R
    Int J Angiol; 2000 Mar; 9(2):82-86. PubMed ID: 10758202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention.
    Toyofyuku M; Imazu M; Sumii K; Yamamoto H; Hayashi Y; Hiyama K; Kohno N
    Atherosclerosis; 2002 Feb; 160(2):339-44. PubMed ID: 11849656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene.
    Koch W; Mehilli J; von Beckerath N; Böttiger C; Schömig A; Kastrati A
    J Am Coll Cardiol; 2003 Jun; 41(11):1957-61. PubMed ID: 12798565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial.
    Meurice T; Bauters C; Hermant X; Codron V; VanBelle E; Mc Fadden EP; Lablanche J; Bertrand ME; Amouyel P
    Lancet; 2001 Apr; 357(9265):1321-4. PubMed ID: 11343737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity.
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Egeland T; Thaulow E
    Am Heart J; 2000 Mar; 139(3):482-90. PubMed ID: 10689263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis.
    Ribichini F; Steffenino G; Dellavalle A; Matullo G; Colajanni E; Camilla T; Vado A; Benetton G; Uslenghi E; Piazza A
    Circulation; 1998 Jan; 97(2):147-54. PubMed ID: 9445166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions.
    Haberbosch W; Bohle RM; Franke FE; Danilov S; Alhenc-Gelas F; Braun-Dullaeus R; Hölschermann H; Waas W; Tillmanns H; Gardemann A
    Atherosclerosis; 1997 Apr; 130(1-2):203-13. PubMed ID: 9126666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1.
    Wijpkema JS; van Haelst PL; Monraats PS; Bruinenberg M; Zwinderman AH; Zijlstra F; van der Steege G; de Winter RJ; Doevendans PA; Waltenberger J; Jukema JW; Tio RA
    Pharmacogenet Genomics; 2006 May; 16(5):331-7. PubMed ID: 16609364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin-angiotensin-aldosterone system (RAAS) gene polymorphism as a risk factor of coronary in-stent restenosis.
    Ryu SK; Cho EY; Park HY; Im EK; Jang YS; Shin GJ; Shim WH; Cho SY
    Yonsei Med J; 2002 Aug; 43(4):461-72. PubMed ID: 12205735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the angiotensin converting enzyme insertion or deletion genetic variant and coronary restenosis risk: evidence based on 11,193 subjects.
    Pan Y; Wang F; Qiu Q; Ding R; Zhao B; Zhou H
    PLoS One; 2013; 8(12):e83415. PubMed ID: 24349507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-converting enzyme gene polymorphism and cardiovascular endocrine system in coronary angiography patients.
    Tsukada K; Ishimitsu T; Tsuchiya N; Horinaka S; Matsuoka H
    Jpn Heart J; 1997 Nov; 38(6):799-810. PubMed ID: 9486933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy.
    Iwai N; Ohmichi N; Nakamura Y; Kinoshita M
    Circulation; 1994 Dec; 90(6):2622-8. PubMed ID: 7994801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans.
    Ohishi M; Ueda M; Rakugi H; Okamura A; Naruko T; Becker AE; Hiwada K; Kamitani A; Kamide K; Higaki J; Ogihara T
    Circulation; 1997 Nov; 96(10):3328-37. PubMed ID: 9396424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.